GLP-1-Analoga: Was ist in der Praxis zu beachten?Seminar/DiabetesGLP-1 Analogs: Recommendations for Clinical Practice

被引：0
作者：
Robert Ritzel
机构：
[1] München Klinik Schwabing und Bogenhausen,Klinik für Endokrinologie, Diabetologie und Angiologie
来源：
MMW - Fortschritte der Medizin | 2020年 / 162卷 / 7期
关键词：
GLP-1; type 2 diabetes ; mellitus; CV-endpoints;
D O I：
10.1007/s15006-020-0390-2
中图分类号：
学科分类号：
摘要：
Bei den seit 2007 in Europa zugelassenen GLP-1-Rezeptoragonisten gibt es immer wieder neue Entwicklungen. Der nachfolgende Beitrag fasst diese zusammen und gibt Handlungsempfehlungen für die Praxis: Für welche Patienten ist diese Therapie sinnvoll? Was ist bei eingeschränkter Nierenfunktion zu beachten? Was können Sie den Patienten raten, um Nebenwirkungen zu vermeiden?
引用
收藏
页码：51 / 54
页数：3
相关论文
共 56 条
[1]  
Pratley RE(2018)Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, openlabel, phase 3b trial Lancet Diabetes Endocrinol 6 27586-85
[2]  
Aroda VR(2019)Cardiovascular, mortality, and kidney outcomes with GLP1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials Lancet Diabetes Endocrinol 7 776-22
[3]  
Lingvay I(2016)Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes N Engl J Med 375 311-8
[4]  
Ludemann J(2020)2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia 63 221-44
[5]  
Andreassen C(2016)Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes N Engl J Med 375 1834-30
[6]  
Navarria A(2019)Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Lancet 394 121-35
[7]  
Kristensen SL(2017)Efficacy and Safety of GLP-1 Receptor Agonists Across the Spectrum of Type 2 Diabetes Mellitus Experimental and Clinical Endocrinology & Diabetes 125 419-47
[8]  
Rorth R(2012)GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation Endocrinology 153 1538-2
[9]  
Jhund PS(2018)No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial Diabetes Care 41 620-9
[10]  
Docherty KF(2018)Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes Diabetes Obes Metab 20 2821-undefined
123456